Nikolaos Trikalinos, MD, MS, Washington University, St. Louis, MO, discusses strategies to make neuroendocrine tumors more susceptible to immune checkpoint inhibitors. Combining immune checkpoint inhibitors with other therapies and treating patients earlier in the course of neuroendocrine tumors may enhance their susceptibility to checkpoint inhibitors. The future holds promise for combining immune checkpoint inhibitors with targeted agents, although more data is needed to establish their efficacy. It is anticipated that specific interventions will be tailored to small subsets of patients who can derive substantial benefits from these approaches. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
